These drug developers will give your portfolio a boost.
News & Analysis: Aurinia Pharmaceuticals
AUPH earnings call for the period ending March 31, 2020.
Could both of these volatile stocks be winners in the long run?
These three developmental-stage pharma stocks are attracting some of the smartest investors right now.
These developers of drugs for cancer, neurological conditions, and rare diseases may boost risk-taking investors' portfolios.
These two biotechs have major drugs that should be hitting the market soon.
Aurinia’s close-to-market products make the company a good investment whether it gets a buyout offer or not.
Amarin and Aurinia will probably be bought out before the end of 2020. Here's why.
The company is raising more money from investors to support development of late-stage drugs.
Find out what made one of these stocks truly skyrocket.